{"id":"https://openalex.org/W2552042013","doi":"https://doi.org/10.1182/blood.v120.21.3868.3868","title":"YM155, a Small-Molecule Survivin Suppressant, Mainly Targets Primary CLL Cells Actively Proliferating and Overcomes Microenvironment-Mediated CLL Cell Protection","display_name":"YM155, a Small-Molecule Survivin Suppressant, Mainly Targets Primary CLL Cells Actively Proliferating and Overcomes Microenvironment-Mediated CLL Cell Protection","publication_year":2012,"publication_date":"2012-11-16","ids":{"openalex":"https://openalex.org/W2552042013","doi":"https://doi.org/10.1182/blood.v120.21.3868.3868","mag":"2552042013"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v120.21.3868.3868","doi":"https://doi.org/10.1182/blood.v120.21.3868.3868","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v120.21.3868.3868","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5032390074","display_name":"Noelia Purroy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102407","display_name":"Vall d'Hebron Institut de Recerca","ror":"https://ror.org/01d5vx451","country_code":"ES","type":"facility","lineage":["https://openalex.org/I4210102407","https://openalex.org/I4387153040"]}],"countries":["ES"],"is_corresponding":true,"raw_author_name":"Noelia Purroy","raw_affiliation_strings":["Laboratory of Experimental Hematology, Vall d'Hebron Research Institute, Barcelona, Spain,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratory of Experimental Hematology, Vall d'Hebron Research Institute, Barcelona, Spain,","institution_ids":["https://openalex.org/I4210102407"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007117385","display_name":"Pau Abrisqueta","orcid":"https://orcid.org/0000-0001-9625-7422","observed_orcids":["https://orcid.org/0000-0001-9625-7422","https://orcid.org/0000-0003-3028-7500"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]}],"countries":["ES"],"is_corresponding":true,"raw_author_name":"Pau Abrisqueta","raw_affiliation_strings":["Department of Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain","institution_ids":["https://openalex.org/I4210127641"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091768140","display_name":"Eva Calpe","orcid":"https://orcid.org/0000-0001-7674-1145","observed_orcids":["https://orcid.org/0000-0001-7674-1145"]},"institutions":[{"id":"https://openalex.org/I4210102407","display_name":"Vall d'Hebron Institut de Recerca","ror":"https://ror.org/01d5vx451","country_code":"ES","type":"facility","lineage":["https://openalex.org/I4210102407","https://openalex.org/I4387153040"]}],"countries":["ES"],"is_corresponding":true,"raw_author_name":"Eva Calpe","raw_affiliation_strings":["Laboratory of Experimental Hematology, Vall d'Hebron Research Institute, Barcelona, Spain,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratory of Experimental Hematology, Vall d'Hebron Research Institute, Barcelona, Spain,","institution_ids":["https://openalex.org/I4210102407"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043920233","display_name":"Cecilia del Carmen Carpio","orcid":"https://orcid.org/0000-0001-9346-0134","observed_orcids":["https://orcid.org/0000-0001-9346-0134"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]}],"countries":["ES"],"is_corresponding":true,"raw_author_name":"Cecilia Carpio","raw_affiliation_strings":["Department of Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain","institution_ids":["https://openalex.org/I4210127641"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070716752","display_name":"Carlos Palacio","orcid":"https://orcid.org/0000-0002-9085-3327","observed_orcids":["https://orcid.org/0000-0002-9085-3327"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]}],"countries":["ES"],"is_corresponding":true,"raw_author_name":"Carles Palacio","raw_affiliation_strings":["Department of Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain","institution_ids":["https://openalex.org/I4210127641"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083842214","display_name":"Laura Gallur","orcid":"https://orcid.org/0000-0001-6293-9281","observed_orcids":["https://orcid.org/0000-0001-6293-9281"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]}],"countries":["ES"],"is_corresponding":true,"raw_author_name":"Laura Gallur","raw_affiliation_strings":["Department of Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain","institution_ids":["https://openalex.org/I4210127641"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039369538","display_name":"Marta Crespo","orcid":"https://orcid.org/0000-0002-7732-7808","observed_orcids":["https://orcid.org/0000-0002-7732-7808"]},"institutions":[{"id":"https://openalex.org/I4210102407","display_name":"Vall d'Hebron Institut de Recerca","ror":"https://ror.org/01d5vx451","country_code":"ES","type":"facility","lineage":["https://openalex.org/I4210102407","https://openalex.org/I4387153040"]}],"countries":["ES"],"is_corresponding":true,"raw_author_name":"Marta Crespo","raw_affiliation_strings":["Laboratory of Experimental Hematology, Vall d'Hebron Research Institute, Barcelona, Spain,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratory of Experimental Hematology, Vall d'Hebron Research Institute, Barcelona, Spain,","institution_ids":["https://openalex.org/I4210102407"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5054008156","display_name":"Francesc Bosch","orcid":"https://orcid.org/0000-0001-9241-2886","observed_orcids":["https://orcid.org/0000-0001-9241-2886"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Francesc Bosch","raw_affiliation_strings":["Department of Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain","institution_ids":["https://openalex.org/I4210127641"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5007117385","https://openalex.org/A5032390074","https://openalex.org/A5039369538","https://openalex.org/A5043920233","https://openalex.org/A5070716752","https://openalex.org/A5083842214","https://openalex.org/A5091768140"],"corresponding_institution_ids":["https://openalex.org/I4210102407","https://openalex.org/I4210127641"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.2045,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.55804816,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"120","issue":"21","first_page":"3868","last_page":"3868"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ym155","display_name":"YM155","score":0.9959999918937683},{"id":"https://openalex.org/keywords/survivin-inhibitor","display_name":"survivin inhibitor","score":0.7540000081062317},{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9990000128746033},{"id":"https://openalex.org/keywords/mesenchymal-stem-cells","display_name":"mesenchymal stem cells","score":0.8199999928474426},{"id":"https://openalex.org/keywords/cd40-ligand","display_name":"CD40 ligand","score":0.7480000257492065},{"id":"https://openalex.org/keywords/cpg-oligodeoxynucleotides","display_name":"CpG oligodeoxynucleotides","score":0.9580000042915344},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.609000027179718},{"id":"https://openalex.org/keywords/fludarabine","display_name":"fludarabine","score":0.859000027179718},{"id":"https://openalex.org/keywords/primary-cll-cells","display_name":"primary CLL cells","score":0.75},{"id":"https://openalex.org/keywords/ki-67","display_name":"Ki-67","score":0.6669999957084656},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.3919999897480011},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.3529999852180481},{"id":"https://openalex.org/keywords/bcl-2","display_name":"Bcl-2","score":0.33399999141693115}],"concepts":[{"id":"https://openalex.org/C2775975398","wikidata":"https://www.wikidata.org/wiki/Q906904","display_name":"Survivin","level":3,"score":0.8742796182632446},{"id":"https://openalex.org/C2775934118","wikidata":"https://www.wikidata.org/wiki/Q424169","display_name":"Propidium iodide","level":4,"score":0.6392800807952881},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6322879195213318},{"id":"https://openalex.org/C16930146","wikidata":"https://www.wikidata.org/wiki/Q4381253","display_name":"Stromal cell","level":2,"score":0.5502141714096069},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.5211694240570068},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.5096936225891113},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.4768058955669403},{"id":"https://openalex.org/C553184892","wikidata":"https://www.wikidata.org/wiki/Q1141429","display_name":"Flow cytometry","level":2,"score":0.45883554220199585},{"id":"https://openalex.org/C2779263901","wikidata":"https://www.wikidata.org/wiki/Q185916","display_name":"Fludarabine","level":4,"score":0.4417306184768677},{"id":"https://openalex.org/C96232424","wikidata":"https://www.wikidata.org/wiki/Q4118072","display_name":"Cancer cell","level":3,"score":0.4122983515262604},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.4103383421897888},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3921651840209961},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3873318135738373},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.3813158869743347},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3810538053512573},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.32558315992355347},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.16356971859931946},{"id":"https://openalex.org/C31573885","wikidata":"https://www.wikidata.org/wiki/Q304484","display_name":"Programmed cell death","level":3,"score":0.12852782011032104},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.1249101459980011},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v120.21.3868.3868","doi":"https://doi.org/10.1182/blood.v120.21.3868.3868","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v120.21.3868.3868","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9789000153541565,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2015638920","https://openalex.org/W2554506924","https://openalex.org/W2512749101","https://openalex.org/W2738254673","https://openalex.org/W2621556501","https://openalex.org/W2512338486","https://openalex.org/W2566948019","https://openalex.org/W2078161165","https://openalex.org/W4255422116","https://openalex.org/W2276858384"],"abstract_inverted_index":{"Abstract":[0,1],"3868":[2],"Chronic":[3],"lymphocytic":[4],"leukemia":[5],"(CLL)":[6],"has":[7,83,567],"been":[8],"historically":[9],"considered":[10],"an":[11,442,480],"accumulative":[12],"disease.":[13],"However,":[14],"recent":[15],"studies":[16],"demonstrate":[17],"the":[18,123,135,142,311,316,339,356,359,384,429,455,460,477,509,512,529,597],"relevance":[19],"of":[20,65,92,125,171,221,230,239,274,303,318,331,347,361,380,386,392,423,431,439,457,511,611],"proliferation":[21,37,60,143,537,565],"centers":[22],"found":[23],"in":[24,52,59,67,88,106,117,131,141,178,180,184,207,251,263,296,299,349,364,404,425,482,531,585,605],"lymphoid":[25],"organs":[26],"(lymph":[27],"nodes":[28],"[LN]":[29],"and":[30,36,97,100,161,233,538,564,566],"bone":[31],"marrow":[32],"[BM]),which":[33],"provide":[34],"survival":[35],"signals":[38,527],"to":[39,76,343,372,487,558,590,599,613],"CLL":[40,53,70,128,146,188,248,280,286,362,540,573,587],"cells.":[41,281,574],"In":[42,551],"CLL,":[43],"immunohistochemical":[44],"analyses":[45],"show":[46,524],"that":[47,55,137,267,444,476,525,578],"survivin":[48,66,81,113,205,275,604],"is":[49,103,114,276,556],"mainly":[50,277],"expressed":[51,116],"cells":[54,71,129,147,156,179,189,249,287,348,363,403,541,588],"are":[56,139],"actively":[57,571],"proliferating":[58,118,279,572,586],"centers.":[61,144],"Interestingly,":[62],"increased":[63,358],"expression":[64,206],"peripheral":[68],"blood":[69],"correlates":[72],"with":[73,153,158,193,214,284,289,433,491,496],"worse":[74],"response":[75,165],"treatment.":[77],"YM155":[78,126,194,215,240,320,417,432,458,492,554,579],"(Astellas\u00ae),":[79],"a":[80,89,132,395,420,436],"suppressant,":[82],"demonstrated":[84],"promising":[85],"antitumoral":[86],"activity":[87],"wide":[90],"variety":[91],"human":[93],"cancer":[94],"cell":[95,269,562],"lines":[96],"xenograft":[98],"models,":[99],"nowadays":[101],"it":[102,254],"being":[104],"evaluated":[105],"several":[107],"phase":[108,366],"II":[109],"clinical":[110,601],"trials.":[111],"As":[112],"usually":[115],"cells,":[119],"herein":[120],"we":[121,452,474],"tested":[122],"effects":[124],"on":[127,369,459,570],"co-cultured":[130,152],"system":[133],"mimicking":[134],"conditions":[136],"they":[138],"encountering":[140],"Primary":[145],"from":[148,367,528,542],"20":[149],"patients":[150],"were":[151,190,351],"BM":[154],"stromal":[155],"along":[157],"CD40":[159],"ligand":[160],"oligodeoxynucleotides-CpG.":[162],"Optimal":[163],"proliferative":[164,264,461,500],"was":[166,209,223,241,255],"observed":[167,475],"after":[168,389],"48":[169,390],"hours":[170,376,391,401],"co-culture":[172,297,357,393,478],"(mean":[173],"%":[174],"Ki-67":[175],"expression,":[176,427],"1.52\u00b10.06":[177],"suspension":[181,300,350],"vs.":[182,306,336],"11.78\u00b16.73":[183],"co-culture,":[185,208],"p<0.001).":[186],"Therefore,":[187],"subsequently":[191],"treated":[192,288],"and/or":[195],"fludarabine":[196,291,335,434,445,497,582,591],"at":[197,353,374,399],"this":[198,322,483,499,552],"time":[199],"point.":[200],"By":[201],"Western":[202],"Blot,":[203],"increasing":[204,326],"completely":[210],"abrogated":[211],"by":[212,225,272,324,464,518,545],"treatment":[213,283,418,555],"50nM":[216,319],"for":[217,247,334,338],"24":[218],"hours.":[219],"Induction":[220],"apoptosis":[222,543],"assessed":[224],"flow":[226],"cytometry":[227],"(FC)":[228],"measurement":[229],"annexin":[231],"V":[232],"propidium":[234],"iodide":[235],"(PI).":[236],"Mean":[237],"LD50":[238],"430.4":[242],"nM":[243],"(95%CI":[244],"227.3\u2013815.3":[245],"nM)":[246,262],"cultured":[250],"suspension,":[252],"whereas":[253,355,428,508],"7.7":[256],"times":[257],"lower":[258],"(56.25nM,":[259],"95%CI":[260],"39.71\u201379.7":[261],"conditions,":[265],"revealing":[266],"apoptotic":[268],"death":[270],"induced":[271,394,479,544],"inhibition":[273],"affecting":[278],"Unlike":[282],"YM155,":[285,382,411],"5\u03bcg/ml":[290],"showed":[292],"significantly":[293,325],"higher":[294],"viability":[295],"than":[298],"(normalized":[301,329],"mean":[302,330],"viability:":[304,332],"60.2%\u00b116.9%":[305],"23.4%\u00b17.1%,":[307],"p<0.001),":[308],"thus":[309],"confirming":[310],"microenvironment-induced":[312],"chemoresistance.":[313],"Of":[314],"note,":[315],"addition":[317,379],"overcame":[321],"chemoresistance":[323],"fludarabine-induced":[327],"cytotoxicity":[328],"42.1%\u00b17.6%":[333],"5.2%\u00b11.9%":[337],"combination;":[340],"p<0.05).":[341,489],"Prior":[342],"any":[344],"treatment,":[345],"98.54%\u00b10.12%":[346],"arrested":[352],"G0/G1,":[354],"number":[360],"S/G2/M":[365],"0.89%\u00b10.31%":[368],"day":[370],"0":[371],"44.96%\u00b123%":[373],"72":[375,400],"(p=0.05).":[377],"The":[378],"fludarabine,":[381,409],"or":[383,494],"combination":[385,430],"both":[387],"drugs":[388],"significant":[396,437],"G1":[397,405],"arrest":[398],"(%":[402],"phase:":[406],"control,":[407],"55.04%\u00b113.28%;":[408],"88.26%\u00b17.94%;":[410],"81.61%\u00b18.47%;":[412],"combination,":[413],"90.75\u00b14.68;":[414],"p<0.01).":[415],"Finally,":[416,593],"caused":[419,435],"drastic":[421],"reduction":[422],"23.31%\u00b19.52%":[424],"Ki67":[426],"decrease":[438],"49.64%\u00b14.12%":[440],"(p<0.001),":[441],"effect":[443,456,569],"alone":[446,493],"could":[447],"not":[448,516],"achieve.":[449],"Following":[450],"this,":[451],"also":[453],"analyzed":[454],"compartment":[462],"defined":[463],"Calissano,":[465],"C":[466],"et":[467],"al":[468],"(Mol":[469],"Med,":[470],"2011;":[471],"CD5high/CXCR4dim).":[472],"Firstly,":[473],"increase":[481],"fraction":[484,501],"(from":[485],"3.28%\u00b11.12%":[486],"9.66%\u00b12.83%,":[488],"Treatment":[490],"combined":[495],"reduced":[498],"(control:":[502],"13.29%\u00b14.21%;":[503],"YM155:":[504],"5.82%\u00b11.24%[p<0.05];":[505],"combination:":[506],"4.12%\u00b11.14%[p<0.01]),":[507],"proportion":[510],"non-proliferative":[513],"compartments":[514],"where":[515],"affected":[517],"these":[519,522,594],"treatments.":[520],"Altogether,":[521],"data":[523],"reproducing":[526],"microenvironment":[530],"ex":[532],"vivo":[533],"co-cultures":[534],"can":[535],"promote":[536],"protect":[539],"cytotoxic":[546],"agents":[547],"such":[548],"as":[549],"fludarabine.":[550],"setting,":[553],"able":[557],"efficiently":[559],"overcome":[560],"microenvironment-mediated":[561],"protection":[563],"specific":[568],"Combination":[575],"experiments":[576],"revealed":[577],"strongly":[580],"potentiates":[581],"cytotoxicity,":[583],"especially":[584],"chemoresistants":[589],"alone.":[592],"results":[595],"open":[596],"door":[598],"future":[600],"trials":[602],"inhibiting":[603],"CLL.":[606],"Disclosures:":[607],"No":[608],"relevant":[609],"conflicts":[610],"interest":[612],"declare.":[614]},"counts_by_year":[{"year":2015,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-11-30T00:00:00"}